Cempra Inc (CEMP) 43.86 $CEMP
Non-Alcoholic Steatohepatitis Clinical Trials Review, H1, 2015
M2 - Tue Aug 04, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ks9fl3/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015" report to their offering. Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015 provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Genextra S.p.a. - Genfit SA - Cempra, Inc. - Raptor Pharmaceuticals Corp. - Nimbus Therapeutics, LLC - Immuron Limited - Gilead Sciences, Inc. - Galmed International Ltd. - Galectin Therapeutics, Inc. - DURECT Corporation Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - University of California, San Diego - National Nutrition and Food Technology Research Institute - Yokohama City University - Bambino Gesu Hospital and Research Institute - Ghent University Hospital - Gunma Liver Study Group - Hadassah Medical Organization - Hiroshima University Hospital For more information visit http://www.researchandmarkets.com/research/ks...nalcoholic
RPTP: 14.28 (+0.40), GILD: 118.66 (-0.21), GALT: 2.56 (-0.09), DRRX: 2.30 (-0.06), CEMP: 43.86 (+0.81)
Global Gonorrhea Clinical Trials Review 2015
M2 - Tue Aug 04, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzj9kq/gonorrhea_global) has announced the addition of the "Gonorrhea Global Clinical Trials Review, H1, 2015" report to their offering. Gonorrhea Global Clinical Trials Review, H1, 2015 provides data on the Gonorrhea clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gonorrhea. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gonorrhea. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Gonorrhea Therapeutics Clinical Trials - Cempra, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Kendle International Inc. (Inactive) - GlaxoSmithKline plc - Endo International plc - ClinicalRM, Inc. - Cempra Pharmaceuticals, Inc. - AstraZeneca PLC Clinical Trial Overview of Top Institutes / Government - Population Council - University of Washington - Washington University School of Medicine - Barts and The London NHS Trust - Center Hospitalier Universitaire de Quebec - Eunice Kennedy Shriver National Institute of Child Health and Human Development - FHI 360 - The National Institute of Allergy and Infectious Diseases - University of California, Los Angeles - University of California, San Diego For more information visit http://www.researchandmarkets.com/research/bz...hea_global
MRK: 59.10 (+0.40), AZN: 34.54 (+0.20), GSK: 44.17 (+0.72), CEMP: 43.86 (+0.81)
Cempra to Present at the Wedbush PacGrow 2015 Healthcare Conference
GlobeNewswire - Tue Aug 04, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Wedbush PacGrow 2015 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 4:15 p.m. EDT (1:15 p.m. PDT) on Tuesday, August 11, 2015 in New York.
CEMP: 43.86 (+0.81)
Why Cempra Inc Shares Fell Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jul 30, 3:26PM CDT
What: Shares of Cempra Inc , a clinical-stage pharmaceutical company with a focus on creating products for antibiotics-resistant bacteria, fell as much as 10% today after reporting second quarter earnings. So what: Revenue during the quarter...
CEMP: 43.86 (+0.81)
Cempra reports 2Q loss
Automated Insights - Wed Jul 29, 4:48PM CDT
CHAPEL HILL, N.C. (AP) _ Cempra Inc. (CEMP) on Wednesday reported a loss of $25 million in its second quarter.
CEMP: 43.86 (+0.81)
Cempra Reports Second Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Wed Jul 29, 3:04PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended June 30, 2015 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 4:30 p.m. EDT.
CEMP: 43.86 (+0.81)
Cempra to Report Second Quarter 2015 Financial Results
GlobeNewswire - Wed Jul 22, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report second quarter 2015 financial results after the close of U.S. financial markets on July 29, 2015. Cempra management will host a webcast and conference call at 4:30 p.m. EDT that day to discuss the financial results and provide a corporate update.
CEMP: 43.86 (+0.81)
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vw27k3/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline plc - Melinta Therapeutics, Inc - Phosphagenics Limited Drug Profiles - CG-400549 - Debio-1450 - Debio-1452 - delafloxacin - fusidic acid - GSK-2140944 - iclaprim mesylate - lanopepden - Small Molecule for Skin Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - tedizolid phosphate For more information visit http://www.researchandmarkets.com/research/vw...cated_skin
GSK: 44.17 (+0.72), CEMP: 43.86 (+0.81)
Cempra Completes Patient Enrollment of Solitaire-IV Phase 3 Clinical Trial
GlobeNewswire - Tue Jul 07, 6:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the completion of enrollment for the global Solitaire-IV Phase 3 trial of solithromycin in adult patients with moderate to moderately severe community-acquired bacterial pneumonia (CABP). Top-line efficacy and safety data from this study are expected to be announced by the end of the year.
CEMP: 43.86 (+0.81)
InsiderInsights.com Daily Round Up 6/24/15: Groupon, Allstate, La Jolla Pharmaceutical And Patriot National
InsiderInsights - at Seeking Alpha - Thu Jun 25, 10:12AM CDT
FIS: 65.74 (+0.46), RATE: 10.16 (+1.19), HCOM: 23.88 (-0.12), ATLS: 2.15 (-0.48), LJPC: 30.62 (+1.16), SAM: 233.22 (-1.56), ILMN: 215.86 (+1.55), CUB: 45.92 (+0.99), ALL: 62.50 (+0.16), GOOG: 643.78 (+14.53), DDR: 16.09 (-0.05), PN: 18.93 (+0.30), NVLS: 17.69 (+0.39), FOGO: 20.13 (+0.28), CEMP: 43.86 (+0.81), GRPN: 4.76 (+0.03), TWTR: 28.48 (-0.86), AMWD: 63.03 (-0.34), FPRX: 25.02 (+0.15)
Achaogen: An Undervalued Antibiotics Pharma Company
Small Pharma Analyst - at Seeking Alpha - Tue Jun 16, 4:00AM CDT
TTPH: 46.50 (-0.39), AKAO: 7.21 (+0.05), PRTK: 23.59 (-2.05), CEMP: 43.86 (+0.81)
Diabetic Gastroparesis Therapeutics Pipeline Review, H1 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu Jun 11, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxgxkz/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc - Targacept, Inc. Drug Profiles - camicinal - ETX-101 - ETX-301 - IW-9179 - metoclopramide hydrochloride - prucalopride succinate - relamorelin - Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - TC-6499 - velusetrag For more information visit http://www.researchandmarkets.com/research/cxgxkz/diabetic
EVOK: 4.99 (-0.01), IRWD: 10.72 (+0.10), TRGT: 2.40 (+0.05), SHPG: 253.75 (+0.15), GSK: 44.17 (+0.72), CEMP: 43.86 (+0.81)
Cempra to Present at the Jefferies 2015 Global Healthcare Conference
GlobeNewswire - Tue May 26, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2015 Global Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, June 2, 2015 in New York.
CEMP: 43.86 (+0.81)
Cempra Presenting Additional Data From the Phase 3 Oral Solithromycin Study in Community Acquired Bacterial Pneumonia at the American Thoracic Society Conference
GlobeNewswire - Tue May 19, 6:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, is presenting results from its Phase 3 clinical trial demonstrating the statistical non-inferiority of oral solithromycin versus oral moxifloxacin for the treatment of community acquired bacterial pneumonia (CABP). Oral solithromycin demonstrated statistical non-inferiority to oral moxifloxacin for the treatment of CABP and the solithromycin early clinical response (ECR) and short term follow-up (SFU) rates were numerically higher than moxifloxacin in the elderly, the patients at greatest risk for CABP. Solithromycin was non-inferior to moxifloxacin on every pre-specified outcome measure in the study. These results will be presented at the American Thoracic Society (ATS) International Conference 2015 at 9:30 a.m. MDT (11:30 a.m. EDT) today in Denver.
CEMP: 43.86 (+0.81)
Cempra to Present Solithromycin Data at Two Upcoming Medical Conferences
GlobeNewswire - Tue May 12, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the American Thoracic Society (ATS) International Conference 2015, May 15-20, and the Community Acquired Pneumonia Organization (CAPO) Symposium on May 20-21. Both meetings are being held in Denver.
CEMP: 43.86 (+0.81)
Cempra's (CEMP) CEO Prabha Fernandes on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun May 03, 8:00AM CDT
CEMP: 43.86 (+0.81)
Pharma Stocks Technical Data -- Akorn, VIVUS, Mallinckrodt, Novo Nordisk, and Cempra
PR Newswire - Fri May 01, 7:30AM CDT
Investor-Edge has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), VIVUS Inc. (NASDAQ: VVUS), Mallinckrodt PLC (NYSE: MNK), Novo Nordisk A/S (NYSE: NVO), and Cempra Inc. (NASDAQ: CEMP). Free research report on Akorn can be accessed at http://get.Investor-Edge.com/pdf/?c=Akorn&...amp;s=AKRX. The US markets declined on Thursday, April 30, 2015, as the Dow Jones Industrial Average finished at 17,840.52, down 1.08% and the NASDAQ Composite closed at 4,941.42, down 1.64%. The S&P 500 finished the session 1.01% lower at 2,085.51. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index ended the day at 828.85, down 1.45%, whereas the index has advanced 3.44% in the previous three months. Register for your complimentary reports at the links given below.
MNK: 104.51 (-2.22), NVO: 59.86 (unch), AKRX: 45.12 (-0.74), VVUS: 1.30 (unch), CEMP: 43.86 (+0.81)
CEMPRA beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Apr 30, 3:11PM CDT
CEMP: 43.86 (+0.81)
Cempra Reports First Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Apr 30, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended March 31, 2015 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 4:30 p.m. EDT.
CEMP: 43.86 (+0.81)
Non-Alcoholic Steatohepatitis Clinical Trials Review, H1, 2015
M2 - Tue Aug 04, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ks9fl3/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015" report to their offering. Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015 provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Genextra S.p.a. - Genfit SA - Cempra, Inc. - Raptor Pharmaceuticals Corp. - Nimbus Therapeutics, LLC - Immuron Limited - Gilead Sciences, Inc. - Galmed International Ltd. - Galectin Therapeutics, Inc. - DURECT Corporation Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - University of California, San Diego - National Nutrition and Food Technology Research Institute - Yokohama City University - Bambino Gesu Hospital and Research Institute - Ghent University Hospital - Gunma Liver Study Group - Hadassah Medical Organization - Hiroshima University Hospital For more information visit http://www.researchandmarkets.com/research/ks...nalcoholic
RPTP: 14.28 (+0.40), GILD: 118.66 (-0.21), GALT: 2.56 (-0.09), DRRX: 2.30 (-0.06), CEMP: 43.86 (+0.81)
Global Gonorrhea Clinical Trials Review 2015
M2 - Tue Aug 04, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzj9kq/gonorrhea_global) has announced the addition of the "Gonorrhea Global Clinical Trials Review, H1, 2015" report to their offering. Gonorrhea Global Clinical Trials Review, H1, 2015 provides data on the Gonorrhea clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gonorrhea. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gonorrhea. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Gonorrhea Therapeutics Clinical Trials - Cempra, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Kendle International Inc. (Inactive) - GlaxoSmithKline plc - Endo International plc - ClinicalRM, Inc. - Cempra Pharmaceuticals, Inc. - AstraZeneca PLC Clinical Trial Overview of Top Institutes / Government - Population Council - University of Washington - Washington University School of Medicine - Barts and The London NHS Trust - Center Hospitalier Universitaire de Quebec - Eunice Kennedy Shriver National Institute of Child Health and Human Development - FHI 360 - The National Institute of Allergy and Infectious Diseases - University of California, Los Angeles - University of California, San Diego For more information visit http://www.researchandmarkets.com/research/bz...hea_global
MRK: 59.10 (+0.40), AZN: 34.54 (+0.20), GSK: 44.17 (+0.72), CEMP: 43.86 (+0.81)
Cempra to Present at the Wedbush PacGrow 2015 Healthcare Conference
GlobeNewswire - Tue Aug 04, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Wedbush PacGrow 2015 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 4:15 p.m. EDT (1:15 p.m. PDT) on Tuesday, August 11, 2015 in New York.
CEMP: 43.86 (+0.81)
Why Cempra Inc Shares Fell Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jul 30, 3:26PM CDT
What: Shares of Cempra Inc , a clinical-stage pharmaceutical company with a focus on creating products for antibiotics-resistant bacteria, fell as much as 10% today after reporting second quarter earnings. So what: Revenue during the quarter...
CEMP: 43.86 (+0.81)
Cempra reports 2Q loss
Automated Insights - Wed Jul 29, 4:48PM CDT
CHAPEL HILL, N.C. (AP) _ Cempra Inc. (CEMP) on Wednesday reported a loss of $25 million in its second quarter.
CEMP: 43.86 (+0.81)
Cempra Reports Second Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Wed Jul 29, 3:04PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended June 30, 2015 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 4:30 p.m. EDT.
CEMP: 43.86 (+0.81)
Cempra to Report Second Quarter 2015 Financial Results
GlobeNewswire - Wed Jul 22, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report second quarter 2015 financial results after the close of U.S. financial markets on July 29, 2015. Cempra management will host a webcast and conference call at 4:30 p.m. EDT that day to discuss the financial results and provide a corporate update.
CEMP: 43.86 (+0.81)
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vw27k3/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline plc - Melinta Therapeutics, Inc - Phosphagenics Limited Drug Profiles - CG-400549 - Debio-1450 - Debio-1452 - delafloxacin - fusidic acid - GSK-2140944 - iclaprim mesylate - lanopepden - Small Molecule for Skin Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - tedizolid phosphate For more information visit http://www.researchandmarkets.com/research/vw...cated_skin
GSK: 44.17 (+0.72), CEMP: 43.86 (+0.81)
Cempra Completes Patient Enrollment of Solitaire-IV Phase 3 Clinical Trial
GlobeNewswire - Tue Jul 07, 6:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the completion of enrollment for the global Solitaire-IV Phase 3 trial of solithromycin in adult patients with moderate to moderately severe community-acquired bacterial pneumonia (CABP). Top-line efficacy and safety data from this study are expected to be announced by the end of the year.
CEMP: 43.86 (+0.81)
InsiderInsights.com Daily Round Up 6/24/15: Groupon, Allstate, La Jolla Pharmaceutical And Patriot National
InsiderInsights - at Seeking Alpha - Thu Jun 25, 10:12AM CDT
FIS: 65.74 (+0.46), RATE: 10.16 (+1.19), HCOM: 23.88 (-0.12), ATLS: 2.15 (-0.48), LJPC: 30.62 (+1.16), SAM: 233.22 (-1.56), ILMN: 215.86 (+1.55), CUB: 45.92 (+0.99), ALL: 62.50 (+0.16), GOOG: 643.78 (+14.53), DDR: 16.09 (-0.05), PN: 18.93 (+0.30), NVLS: 17.69 (+0.39), FOGO: 20.13 (+0.28), CEMP: 43.86 (+0.81), GRPN: 4.76 (+0.03), TWTR: 28.48 (-0.86), AMWD: 63.03 (-0.34), FPRX: 25.02 (+0.15)
Achaogen: An Undervalued Antibiotics Pharma Company
Small Pharma Analyst - at Seeking Alpha - Tue Jun 16, 4:00AM CDT
TTPH: 46.50 (-0.39), AKAO: 7.21 (+0.05), PRTK: 23.59 (-2.05), CEMP: 43.86 (+0.81)
Diabetic Gastroparesis Therapeutics Pipeline Review, H1 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu Jun 11, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxgxkz/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc - Targacept, Inc. Drug Profiles - camicinal - ETX-101 - ETX-301 - IW-9179 - metoclopramide hydrochloride - prucalopride succinate - relamorelin - Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - TC-6499 - velusetrag For more information visit http://www.researchandmarkets.com/research/cxgxkz/diabetic
EVOK: 4.99 (-0.01), IRWD: 10.72 (+0.10), TRGT: 2.40 (+0.05), SHPG: 253.75 (+0.15), GSK: 44.17 (+0.72), CEMP: 43.86 (+0.81)
Cempra to Present at the Jefferies 2015 Global Healthcare Conference
GlobeNewswire - Tue May 26, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2015 Global Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, June 2, 2015 in New York.
CEMP: 43.86 (+0.81)
Cempra Presenting Additional Data From the Phase 3 Oral Solithromycin Study in Community Acquired Bacterial Pneumonia at the American Thoracic Society Conference
GlobeNewswire - Tue May 19, 6:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, is presenting results from its Phase 3 clinical trial demonstrating the statistical non-inferiority of oral solithromycin versus oral moxifloxacin for the treatment of community acquired bacterial pneumonia (CABP). Oral solithromycin demonstrated statistical non-inferiority to oral moxifloxacin for the treatment of CABP and the solithromycin early clinical response (ECR) and short term follow-up (SFU) rates were numerically higher than moxifloxacin in the elderly, the patients at greatest risk for CABP. Solithromycin was non-inferior to moxifloxacin on every pre-specified outcome measure in the study. These results will be presented at the American Thoracic Society (ATS) International Conference 2015 at 9:30 a.m. MDT (11:30 a.m. EDT) today in Denver.
CEMP: 43.86 (+0.81)
Cempra to Present Solithromycin Data at Two Upcoming Medical Conferences
GlobeNewswire - Tue May 12, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the American Thoracic Society (ATS) International Conference 2015, May 15-20, and the Community Acquired Pneumonia Organization (CAPO) Symposium on May 20-21. Both meetings are being held in Denver.
CEMP: 43.86 (+0.81)
Cempra's (CEMP) CEO Prabha Fernandes on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun May 03, 8:00AM CDT
CEMP: 43.86 (+0.81)
Pharma Stocks Technical Data -- Akorn, VIVUS, Mallinckrodt, Novo Nordisk, and Cempra
PR Newswire - Fri May 01, 7:30AM CDT
Investor-Edge has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), VIVUS Inc. (NASDAQ: VVUS), Mallinckrodt PLC (NYSE: MNK), Novo Nordisk A/S (NYSE: NVO), and Cempra Inc. (NASDAQ: CEMP). Free research report on Akorn can be accessed at http://get.Investor-Edge.com/pdf/?c=Akorn&...amp;s=AKRX. The US markets declined on Thursday, April 30, 2015, as the Dow Jones Industrial Average finished at 17,840.52, down 1.08% and the NASDAQ Composite closed at 4,941.42, down 1.64%. The S&P 500 finished the session 1.01% lower at 2,085.51. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index ended the day at 828.85, down 1.45%, whereas the index has advanced 3.44% in the previous three months. Register for your complimentary reports at the links given below.
MNK: 104.51 (-2.22), NVO: 59.86 (unch), AKRX: 45.12 (-0.74), VVUS: 1.30 (unch), CEMP: 43.86 (+0.81)
CEMPRA beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Apr 30, 3:11PM CDT
CEMP: 43.86 (+0.81)
Cempra Reports First Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Apr 30, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended March 31, 2015 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 4:30 p.m. EDT.
CEMP: 43.86 (+0.81)
